Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors

    loading  Checking for direct PDF access through Ovid

Abstract

This report demonstrates a unique case of conjunctival melanoma harboring a BRAF V600E mutation responsive to systemic therapy with BRAF and MEK inhibitors. While systemic therapy would not be appropriate in patients with local disease alone, it may act therapeutically in cases of higher stage ocular surface and eyelid melanoma.

Related Topics

    loading  Loading Related Articles